Pulmonary Toxicity due to Chemotherapy How is the Risk and Benefit from ZD1839 Treatment against Non-Small Cell Lung Cancer?

Okamoto, Isamu; Suga, Moritaka

doi:10.2169/internalmedicine.42.926

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although gefitinib is not typically associated with the general toxic effects of chemotherapy (e.g. hematological toxicity such as neutropenia and leukopenia), some evidence, including reports from the studies previously discussed, has indicated that a proportion of patients receiving gefitinib experience interstitial lung disease (ILD) 10,23,32,37,41,44–48 . As of January 2006, more than 215 000 patients worldwide are estimated to have been treated with gefitinib.…”

Section: Methodsmentioning

confidence: 99%

Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin

Armour

2007

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Background: The IRESSA Survival Evaluation in Lung cancer (ISEL) trial showed some improvement in survival which failed to reach statistical significance in the overall population and in patients with adenocarcinoma. However, gefitinib (IRESSA) treatment was associated with a significant improvement in the survival in subgroups of patients of Asian origin and never smokers. Here we review the clinical experience of gefitinib in patients of Asian origin with advanced non-small cell lung cancer (NSCLC) and discuss the evidence for the underlying biological basis for the apparent heterogeneity in clinical outcome between patients of Asian and non-Asian origin. Methods: Reports of clinical experience with gefitinib 250 mg/day in Asia were identified by searching Embase and Medline databases for publications between 1 January 2003 and 27 July 2006. Results: A large number of reports in patients of Asian origin show high objective response and diseasecontrol rates with gefitinib treatment, with median survival >6 months and time to progression >3 months. The reports also indicate that gefitinib is generally well tolerated by patients of Asian origin and epidermal growth factor receptor (EGFR) mutations, which appear to be associated with gefitinib sensitivity, occur at a much higher rate in these patients compared with patients of non-Asian origin. These reports also indicate that a high EGFR gene copy number may be associated with their response to gefitinib. Conclusion: Gefitinib appears to be a valid, efficacious, and generally well-tolerated treatment option for patients of Asian origin with advanced NSCLC. It is possible that differences in EGFR mutation rates may underlie variations in response rates to gefitinib between Asian and non-Asian patient populations. Further exploratory analyses conducted in prospective clinical trials are required to fully determine the role of EGFR mutations, a high EGFR gene copy number and other biomarkers in determining the response to gefitinib treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin

Armour

2007

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…Although gefitinib is not associated with many of the general adverse effects of broadly acting cytotoxic chemotherapeutic agents, recent reports from Japan have indicated that a proportion of patients treated with gefitinib experienced severe ILD (Ieki et al , 2003; Inoue et al , 2003; Okamoto and Suga, 2003; Rabinowits et al , 2003; Sumter et al , 2003). Evaluation of drug causality is also difficult here.…”

mentioning

confidence: 99%

Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management

Camus

2004

Br J Cancer

View full text Add to dashboard Cite

Syndrome de détresse respiratoire aiguë à la gemcitabine d’évolution favorable

Bonnichon

Vedrine

Aletti

et al. 2007

Revue de Pneumologie Clinique

View full text Add to dashboard Cite

Pulmonary Toxicity due to Chemotherapy How is the Risk and Benefit from ZD1839 Treatment against Non-Small Cell Lung Cancer?

Cited by 4 publications

References 8 publications

Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin

Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin

Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management

Syndrome de détresse respiratoire aiguë à la gemcitabine d’évolution favorable

Contact Info

Product

Resources

About